Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Y. Goto
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors Y. Goto1, A. Nakamura1, T. Kishi1, K. Sakanaka1, S. Itasaka2, K. Shibuya3, S. Matsumoto4, Y. Kodama5, K. Takaori6, T. Mizowaki1, M. Hiraoka1
  • 1Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, Kyoto City, Japan, /
  • 2Department of Radiation Oncology, Kurashiki Central Hospital, Kurashiki City, Japan, /
  • 3Department of Therapeutic Radiology, Yamaguchi University Graduate School of Medicine, Ube City, Japan, /
  • 4Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, /
  • 5Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, /
  • 6Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto City, Japan, /

Abstract

Concurrent chemoradiotherapy (CCRT) is considered the treatment option for locally advanced pancreatic cancer (LAPC), but the gastrointestinal (GI) toxicities with CCRT have been reportedly more significant than those with chemotherapy alone. With the introduction of intensity-modulated radiotherapy (IMRT) which can simultaneously reduce the dose to organ at risk and allow an increase in target dose, CCRT-related GI toxicities are expected to decrease. In this study, our aim is to retrospectively evaluate the effect of the introducing IMRT on treatment-related acute and late GI toxicities and outcomes compared to three-dimensional conformal radiotherapy (3DCRT) for LAPC.